Evidence map›Paper›PMID 35262956›Full record

ArticleJournal of cutaneous pathology2022

Comparison of the prognostic value of microscopically measured invasive width versus macroscopic width in cutaneous melanoma shows the superiority of microscopic invasive width measurement.

Mark Bamford, Louisa Udensi, Arushi Khanna, Marie O'Riordan, Gerald Saldanha

Abstract read
In one paragraph

Article in Journal of cutaneous pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mark BamfordDepartment of Cellular Pathology, University Hospitals of Leicester NHS Trust, Leicester, UK.
Louisa UdensiDepartment of Cellular Pathology, University Hospitals of Leicester NHS Trust, Leicester, UK.
Arushi KhannaLeicester Medical School, University of Leicester, Leicester, UK.
Marie O'RiordanDepartment of Cellular Pathology, University Hospitals of Leicester NHS Trust, Leicester, UK.
Gerald SaldanhaDepartment of Cellular Pathology, University Hospitals of Leicester NHS Trust, Leicester, UK.ORCID https://orcid.org/0000-0002-1910-020X

Funding

Association of Clinical Pathologists Intercalated Studies Student GrantBritish Skin Foundation Small Grant S1212Hope Foundation Small Research Grants Programme
6 · The paper itself

Abstract

backgroundInvasive width, the distance between the most peripheral invasive melanoma cells on the section where Breslow thickness (BT) was measured, was recently identified as a prognostic feature. It is unclear whether a routine measurement is justified, given that macroscopic width is already included in many melanoma histopathology reports and may itself be a prognostic feature. This study sought to investigate this.

methodsA retrospective cohort of 718 melanoma patients in which macroscopic width had been stated in the original histopathology report was used. Survival analysis was performed.

resultsMacroscopic and invasive widths were positively correlated (p < 0.001). Invasive width was typically smaller than the paired macroscopic width (median difference 3.7 mm, p < 0.001), a difference seen across all T groups. Both macroscopic and invasive widths were significantly associated with melanoma survival in Kaplan-Meier analysis, including overall survival, but invasive width survival curves were more widely separated. Both were significantly associated with outcome after correction for BT in Cox proportional hazards regression, but the models containing invasive width had a substantially better fit.

conclusionsThis study shows that both macroscopic and invasive widths have prognostic values, but confirms that the latter is superior. It supports further investigation of this feature's prognostic value.

Indexed as

MelanomaSkin NeoplasmsCutaneous Malignant MelanomaHumansNeoplasm StagingPrognosisProportional Hazards ModelsRetrospective Studiesbiomarkercancermalignant melanomaprognosisskin

Identifiers

PMID35262956
PMCPMC9314712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.